
Cancer treatment options are changing as a result of extensive research efforts. New drugs and drug combinations proceed through specific phases of clinical research leading to possible Food and Drug Administration review and approval. Phase I, II, III, and IV clinical trials have detailed enrollment criteria and treatment plans designed to determine research objectives. These objectives can include reduction of toxicity, increased efficacy, and improved quality of life. Liposomal drug formulations, monoclonal antibody therapies, and cytoprotective agents are some of the new treatment approaches that have shown promise in clinical trials. This article reviews the clinical trial process, several innovative therapies, and the nursing responsibilities associated with caring for the patient with cancer.
Bridged-Ring Compounds, Clinical Trials, Phase I as Topic, Oncology Nursing, Antibodies, Monoclonal, Antineoplastic Agents, Clinical Trials, Phase II as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Cytoprotection, Neoplasms, Quality of Life, Humans, Taxoids
Bridged-Ring Compounds, Clinical Trials, Phase I as Topic, Oncology Nursing, Antibodies, Monoclonal, Antineoplastic Agents, Clinical Trials, Phase II as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Cytoprotection, Neoplasms, Quality of Life, Humans, Taxoids
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
